HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Lowers Price Target to $0.5

Benzinga · 3d ago
HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and lowers the price target from $1 to $0.5.